Propanc Biopharma, Inc. $PPCB

What the company doesAI summary of filing

Propanc Biopharma is a pre-revenue biopharmaceutical company developing PRP, a proenzyme therapy consisting of pancreatic enzymes (trypsinogen and chymotrypsinogen) delivered by intravenous injection to treat solid tumors including pancreatic, ovarian, and colorectal cancers. The company is currently in clinical-stage development, having completed preclinical studies and preparation for a Phase Ib clinical trial expected to begin in the second quarter of 2027, with plans to submit a clinical trial application in the fourth quarter of 2026. The company makes money through research collaborations and intellectual property licensing, with anticipated royalties from net product sales (two percent to the University of Bath; two to ten percent to the Universities of Jaén and Granada depending on the agreement). Propanc is pursuing a strategy to develop PRP through Phase II clinical trials and then seek licensing partners for further commercialization. [10-K 2026-09-25]

Segments: PRP (proenzyme therapy for solid tumors), POP1 Program (synthetic proenzyme research and drug discovery)